{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:46:14Z","timestamp":1791866774827,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["Study 221138"],"award-info":[{"award-number":["Study 221138"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-026-01460-y","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:24Z","timestamp":1791825984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible\/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum \u03b2-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes"],"prefix":"10.1007","author":[{"given":"Ryan K.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Lenore","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pinaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Farrell-Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny S.","family":"Mitrani-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"1","key":"1460_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz536","volume":"7","author":"JJ Carreno","year":"2020","unstructured":"Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP Jr. Corrigendum to: longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2020;7(1):ofz536. https:\/\/doi.org\/10.1093\/ofid\/ofz536.","journal-title":"Open Forum Infect Dis"},{"key":"1460_CR2","unstructured":"Sabih A, Leslie SW. Complicated urinary tract infections. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing: 2026."},{"issue":"3","key":"1460_CR3","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0214","volume":"14","author":"F Wagenlehner","year":"2025","unstructured":"Wagenlehner F, Caballero VR, Maheshwari V, et al. Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis. J Comp Eff Res. 2025;14(3):e240214. https:\/\/doi.org\/10.57264\/cer-2024-0214.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1460_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","volume":"77","author":"DA Talan","year":"2021","unstructured":"Talan DA, Takhar SS, Krishnadasan A, et al. Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med. 2021;77(1):32\u201343. https:\/\/doi.org\/10.1016\/j.annemergmed.2020.08.022.","journal-title":"Ann Emerg Med"},{"issue":"11","key":"1460_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112937","volume":"11","author":"A Husna","year":"2023","unstructured":"Husna A, Rahman MM, Badruzzaman ATM, et al. Extended-spectrum \u03b2-lactamases (ESBL): challenges and opportunities. Biomedicines. 2023;11(11):2937. https:\/\/doi.org\/10.3390\/biomedicines11112937.","journal-title":"Biomedicines"},{"key":"1460_CR6","doi-asserted-by":"crossref","unstructured":"Trautner BW, Cortes-Penfield NW, Gupta K, et al. Clinical practice guideline by Infectious Diseases Society of America (IDSA): 2025 guideline on management and treatment of complicated urinary tract infections: Introduction and methods. Clin Infect Dis. 2025:ciaf459","DOI":"10.1093\/cid\/ciaf460"},{"issue":"7","key":"1460_CR7","doi-asserted-by":"publisher","first-page":"ofac307","DOI":"10.1093\/ofid\/ofac307","volume":"9","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Manjelievskaia J, Marchlewicz EH, Rodriguez M. Retrospective cohort study of the 12-month epidemiology, treatment patterns, outcomes, and health care costs among adult patients with complicated urinary tract infections. Open Forum Infect Dis. 2022;9(7):ofac307. https:\/\/doi.org\/10.1093\/ofid\/ofac307.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1460_CR8","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2010","unstructured":"Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2010;52(5):e103\u201320. https:\/\/doi.org\/10.1093\/cid\/ciq257.","journal-title":"Clin Infect Dis"},{"key":"1460_CR9","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024:ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijid.2022.03.052","volume":"119","author":"SI Aronin","year":"2022","unstructured":"Aronin SI, Gupta V, Dunne MW, Watts JA, Yu KC. Regional differences in antibiotic-resistant Enterobacterales urine isolates in the United States: 2018-2020. Int J Infect Dis. 2022;119:142\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2022.03.052.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1460_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115717","volume":"103","author":"SI Aronin","year":"2022","unstructured":"Aronin SI, Dunne MW, Yu KC, Watts JA, Gupta V. Increased rates of extended-spectrum beta-lactamase isolates in patients hospitalized with culture-positive urinary Enterobacterales in the United States: 2011\u20132020. Diagn Microbiol Infect Dis. 2022;103(4):115717. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115717.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1460_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269\u201384. https:\/\/doi.org\/10.1038\/nrmicro3432.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"1460_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1801467.","journal-title":"N Engl J Med"},{"issue":"3","key":"1460_CR14","doi-asserted-by":"publisher","first-page":"dlab02","DOI":"10.1093\/jacamr\/dlab092","volume":"3","author":"M Castanheira","year":"2021","unstructured":"Castanheira M, Simner PJ, Bradford PA. Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021;3(3):dlab02. https:\/\/doi.org\/10.1093\/jacamr\/dlab092.","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"1460_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-e), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. Aeruginosa). Clin Infect Dis. 2022;75(2):187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1460_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/cmr.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657\u201386. https:\/\/doi.org\/10.1128\/cmr.18.4.657-686.2005.","journal-title":"Clin Microbiol Rev"},{"key":"1460_CR17","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0513-2022","volume":"56","author":"MRB Ara\u00fajo","year":"2023","unstructured":"Ara\u00fajo MRB, Sant\u2019Anna LO, Santos NNCD, Seabra LF, Santos LSD. Monitoring fluoroquinolone resistance among ESBL-positive and ESBL-negative Escherichia coli strains isolated from urinary tract infections: An alert for empirical treatment. Rev Soc Bras Med Trop. 2023;56:e0513. https:\/\/doi.org\/10.1590\/0037-8682-0513-2022.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"11","key":"1460_CR18","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/microorganisms12112320","volume":"12","author":"AP Ruiz-Lievano","year":"2024","unstructured":"Ruiz-Lievano AP, Cervantes-Flores F, Nava-Torres A, Carbajal-Morales PJ, Villase\u00f1or-Garcia LF, Zavala-Cerna MG. Fluoroquinolone Resistance in Escherichia coli Causing Community-Acquired Urinary Tract Infections: A Systematic Review. Microorganisms. 2024;12(11):2320. https:\/\/doi.org\/10.3390\/microorganisms12112320.","journal-title":"Microorganisms"},{"issue":"3","key":"1460_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/aac.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969\u201376. https:\/\/doi.org\/10.1128\/aac.01009-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1460_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa480","volume":"9","author":"Y Ezure","year":"2020","unstructured":"Ezure Y, Rico V, Paterson DL, et al. Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: a systematic review and meta-analysis. Open Forum Infect Dis. 2020;9(5):ofaa480. https:\/\/doi.org\/10.1093\/ofid\/ofaa480.","journal-title":"Open Forum Infect Dis"},{"key":"1460_CR21","unstructured":"Optum Inc. Gain visibility into patient care and outcomes with ehr data. Accessed September 15 2026. https:\/\/business.optum.com\/content\/dam\/o4-dam\/resources\/pdfs\/sell-sheets\/ehr-sell-sheet.pdf."},{"issue":"8","key":"1460_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad313","volume":"10","author":"MA Olsen","year":"2023","unstructured":"Olsen MA, Keller MR, Stwalley D, Yu H, Dubberke ER. Increased incidence and risk of septicemia and urinary tract infection after Clostridioides difficile infection. Open Forum Infect Dis. 2023;10(8):ofad313. https:\/\/doi.org\/10.1093\/ofid\/ofad313.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1460_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/cid\/ciy418","volume":"68","author":"N Eliakim-Raz","year":"2019","unstructured":"Eliakim-Raz N, Babitch T, Shaw E, et al. Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: a multicenter retrospective cohort study (RESCUING study group). Clin Infect Dis. 2019;68(1):29\u201336. https:\/\/doi.org\/10.1093\/cid\/ciy418.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1460_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkag112","volume":"81","author":"ME Luck","year":"2026","unstructured":"Luck ME, Martin A, Punja S, et al. Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review. J Antimicrob Chemother. 2026;81(5):dkag112. https:\/\/doi.org\/10.1093\/jac\/dkag112.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01460-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:02:46Z","timestamp":1791864166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01460-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":24,"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01460-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Trademarks are the property of their respective owners (Optum), who have reviewed the content of the manuscript, and provided permission to use the resources included in the manuscript. Ryan K. Shields is a paid consultant to GSK, Roche and bioMerieux; advisor\/consultant for Melinta, Merck, and Shionogi; and received investigator-initiated research funding from Merck, Melinta, and Shionogi. A. Lenore Ackerman is a paid consultant for Abbvie; advisor\/consultant for Watershed Medical, Desert Harvest, LiviWell, NowWell, and GSK. Myriam Drysdale, Iain A. Gillespie, Alanna Farrell-Foster and Fanny S. Mitrani-Gold are employed by GSK and hold financial equities in GSK. Rose Chang, Louise Yu, Maral DerSarkissian, Megan Pinaire, Zhuo Chen, and Mei Sheng Duh are employed by the Analysis Group Inc., who received funding from GSK to complete this study.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with all applicable laws and regulations governing the protection of patient privacy. All information was obtained from the Optum EHR database, which contains fully de-identified data that complies with relevant privacy and confidentiality standards. All analyses, reports, and publications generated from this research used aggregate data only, ensuring that no personally identifiable information was disclosed. This article does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}